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PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and
many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M
against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demon-
strated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staph-
ylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalospo-
rins while maintaining similar activity against gram-negative pathogens.
Gram-positive bacterial pathogens have revealed an extraor-
dinary ability to develop resistance to antimicrobial agents in
the last two decades. Methicillin- and glycopeptide-resistant
staphylococci, glycopeptide-resistant enterococci, and penicil-
lin- and macrolide-resistant Streptococcus pneumoniae and viri-
dans group streptococci have forced clinicians to seek alterna-
tive treatments for patients with serious gram-positive
infections (9). Although a number of new agents have recently
become available to treat infections caused by resistant gram-
positive organisms, all these agents (including daptomycin, lin-
ezolid, and quinupristin-dalfopristin) lack activity against com-
mon gram-negative pathogens, necessitating combination
therapy for empirical treatment of many serious infections.
There is a clinical need for a new broad-spectrum antimicro-
bial agent that covers both resistant gram-positive and gram-
negative pathogens.
PPI-0903 (formerly TAK-599) is a novel N-phosphono-type
prodrug cephalosporin administered intravenously. Its active
form, PPI-0903M, is released in vivo upon hydrolysis of the
phosphonate group (Fig. 1). Preliminary in vitro studies have
indicated that this compound has a high affinity for PBP2 or
PBP2A and shows a potent in vitro activity against MRSA and
many other gram-positive organisms (6, 7). In this report, we
summarize the results of testing PPI-0903M and numerous
comparator agents against contemporary clinical isolates
(2003).
A total of 1,478 strains derived from numerous laboratories
worldwide were processed in the study. These strains included
well-characterized subsets of gram-positive organisms with
specific resistance phenotypes. Only nonduplicate isolates
judged to be clinically significant by local criteria were included
in the study. All isolates were collected in 2003 except some
isolates of the multidrug-resistant groups, which were cultured
over the last 5 years (16).
The PPI-0903M reagent-grade compound was manufac-
tured by Takeda Pharmaceutical, Inc. (Osaka, Japan). Com-
parator agents were purchased from Sigma Chemical Co. (St.
Louis, MO) or obtained from their respective manufacturers in
the United States. A total of 25 comparators were tested de-
pending upon the species evaluated.
PPI-0903M MICs were determined by reference broth mi-
crodilution methods according to procedures published by the
Clinical and Laboratory Standards Institute (CLSI) (formerly
the National Committee for Clinical Laboratory Standards
[NCCLS]) (3, 11, 12). Oxacillin was used in the susceptibility
test to categorize the staphylococcal isolates as methicillin sus-
ceptible or resistant. Supplement 2 to 5% lysed horse blood
was added for testing fastidious Streptococcus spp., and Hae-
mophilus Test Medium was utilized for testing Haemophilus
influenzae. The MICs were interpreted according to CLSI/
NCCLS criteria (3). Quality control was monitored using the
following organisms: S. pneumoniae ATCC 49619, Enterococ-
cus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213,
Escherichia coli ATCC 25923, and Pseudomonas aeruginosa
ATCC 27853. All quality control results were within published
guidelines (3).
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FIG. 1. Chemical structure of PPI-0903 (TAK-599) and PPI-
0903M (T-91825).
3501
TABLE 1. In vitro activities of PPI-0903M compared to those of selected antimicrobial agents when tested against gram-positive bacteria
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Staphylococcus aureus
Methicillin susceptible (73)a
PPI-0903M 0.25 0.25 0.03–0.5 —b —
Cefepime 2 4 0.25–16 98.6 0.0
Ceftriaxone 4 4 0.5–16 98.6 0.0
Piperacillin-tazobactam 1 2 0.12–4 100.0 0.0
Imipenem 0.5 0.5 0.5 100.0 0.0
Levofloxacin 0.12 0.5 0.06–4 93.2 4.1
Vancomycin 1 1 0.5–2 100.0 0.0
Linezolid 2 2 0.5–2 100.0 —
Methicillin resistant (102)a
PPI-0903M 1 2 0.12–2 — —
Cefepime 16 16 1–16 (26.5)c (60.8)c
Ceftriaxone 32 32 4–32 (11.8)c (60.8)c
Piperacillin-tazobactam 64 256 0.5–256 (20.6)c (79.4)c
Imipenem 2 8 0.5–8 (63.7)c (30.4)c
Levofloxacin 4 4 0.12–4 10.8 87.3
Vancomycin 1 1 0.5–4 100.0 0.0
Linezolid 2 2 0.25–2 100.0 —
h-VISA and VISA (100)d
PPI-0903M 1 2 0.25–4 — —
Cefepime 16 16 4–16 7.0 91.0
Ceftriaxone 32 32 4–32 4.0 93.0
Oxacillin 2 2 0.25–2 12.0 88.0
Piperacillin-tazobactam 128 256 1–256 5.0 95.0
Imipenem 8 8 0.5–8 12.0 80.0
Levofloxacin 4 4 0.12–4 1.0 94.0
Linezolid 1 1 0.5–8 99.0 —
Quinupristin-dalfopristin nonsusceptible (11)
PPI-0903M 1 1 0.25–1 — —
Cefepime 16 16 2–16 18.2 63.6
Ceftriaxone 32 32 8–32 9.1 72.7
Oxacillin 8 8 8–8 0.0 100.0
Piperacillin-tazobactam 64 64 4–64 16.7 83.3
Imipenem 8 8 0.06–8 36.4 63.6
Levofloxacin 4 4 1–4 9.1 90.9
Vancomycin 2 2 1–2 100.0 0.0
Linezolid 1 2 0.5–2 100.0 —
CoNS
Methicillin susceptible (50)a
PPI-0903M 0.06 0.25 0.016–0.5 — —
Cefepime 1 2 0.25–2 100.0 0.0
Ceftriaxone 2 4 0.5–8 100.0 0.0
Piperacillin-tazobactam 0.25 1 0.12–4 100.0 0.0
Imipenem 0.5 0.5 0.5 100.0 0.0
Levofloxacin 0.25 1 0.06–4 90.0 8.0
Vancomycin 1 2 0.5–4 100.0 0.0
Linezolid 1 1 0.5–2 100.0 —
Methicillin resistant (80)a
PPI-0903M 0.25 0.5 0.016–2 — —
Cefepime 4 8 1–16 (92.5)c (6.3)c
Ceftriaxone 8 32 4–32 (55.0)c (5.0)c
Piperacillin-tazobactam 1 4 0.25–256 (96.3)c (3.7)c
Imipenem 0.5 2 0.5–8 (92.5)c (6.3)c
Levofloxacin 4 4 0.06–4 37.5 55.0
Vancomycin 2 2 0.12–2 100.0 0.0
Linezolid 1 1 0.25–2 100.0 —
h-VIS (51)e
PPI-0903M 1 2 0.016–2 — —
Continued on following page
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TABLE 1—Continued
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Cefepime 16 16 0.5–16 31.4 62.7
Ceftriaxone 32 32 1–32 15.7 66.7
Oxacillin 8 8 0.25–8 9.8 90.2
Piperacillin-tazobactam 64 64 0.5–64 28.6 71.4
Imipenem 8 8 0.5–8 43.1 56.9
Levofloxacin 4 4 0.12–4 22.5 77.5
Linezolid 1 2 0.5–2 100.0 —
Quinupristin-dalfopristin nonsusceptible (15)
PPI-0903M 0.5 1 0.12–2 — —
Cefepime 8 16 1–16 (60.0)c (26.7)c
Ceftriaxone 32 32 8–32 (33.3)c (40.0)c
Oxacillin 8 8 0.5–8 0.0 100.0
Piperacillin-tazobactam 4 64 1–64 (53.8)c (46.2)c
Imipenem 1 8 0.5–8 (73.3)c (26.7)c
Levofloxacin 4 4 1–4 9.1 72.7
Vancomycin 2 2 0.5–2 100.0 0.0
Linezolid 1 2 1–2 100.0 —
Streptococcus pneumoniae
Penicillin susceptible (33)
PPI-0903M 0.016 0.016 0.016–0.06 — —
Cefepimef 0.06 0.25 0.06–0.5 100.0 0.0
Ceftriaxonef 0.016 0.06 0.016–0.5 100.0 0.0
Meropenem 0.016 0.03 0.008–0.03 100.0 0.0
Levofloxacin 1 1 0.5–1 100.0 0.0
Clarithromycin 0.25 8 0.25–32 81.8 15.2
Erythromycin 0.25 8 0.25–32 81.8 12.1
Vancomycin 0.25 0.5 0.06–0.5 100.0 —
Penicillin intermediate (53)
PPI-0903M 0.03 0.06 0.016–0.12 — —
Cefepimef 0.25 1 0.06–4 95.9 2.0
Ceftriaxonef 0.25 0.5 0.03–1 100.0 0.0
Meropenem 0.12 0.5 0.008–0.5 82.2 0.0
Levofloxacin 1 1 0.12–2 100.0 0.0
Clarithromycin 1 32 0.25–32 36.0 64.0
Erythromycin 2 32 0.25–32 36.0 64.0
Vancomycin 0.25 0.5 0.12–2 98.0 —
Penicillin resistant (50)
PPI-0903M 0.12 0.25 0.06–0.5 — —
Cefepimef 1 2 0.25–4 78.0 2.0
Ceftriaxonef 1 2 0.008–8 82.0 8.0
Meropenem 1 1 0.25–2 2.1 55.3
Levofloxacin 1 1 0.5–1 100.0 0.0
Clarithromycin 8 32 0.25–32 12.0 86.0
Erythromycin 8 32 0.25–32 12.0 88.0
Vancomycin 0.25 0.5 0.12–0.5 100.0 —
Levofloxacin nonsusceptible (22)
PPI-0903M 0.016 0.12 0.016–0.12 — —
Cefepime 0.06 0.5 0.06–1 100.0 0.0
Ceftriaxone 0.03 0.5 0.008–1 100.0 0.0
Penicillin 0.03 1 0.03–2 68.2 9.1
Clarithromycin 2 32 0.25–32 40.9 59.1
Erythromycin 4 32 0.25–32 40.9 59.1
Vancomycin 0.25 0.5 0.12–0.5 100.0 —
Multidrug resistant (23)g
PPI-0903M 0.12 0.25 0.12–0.5 — —
Cefepimef 1 2 0.5–4 73.9 4.3
Ceftriaxonef 1 4 0.008–8 73.9 13.0
Meropenem 1 1 0.5–1 0.0 65.2
Levofloxacin 1 1 0.5–4 95.7 0.0
Vancomycin 0.25 0.5 0.12–0.5 100.0 0.0
Continued on facing page
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TABLE 1—Continued
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
-Haemolytic group A streptococci (22)
PPI-0903M 0.016 0.016 0.016 — —
Cefepime 0.12 0.12 0.12 100.0 0.0
Ceftriaxone 0.25 0.25 0.25 100.0 0.0
Penicillin 0.016 0.016 0.016–0.03 100.0 0.0
Meropenem 0.008 0.008 0.008 100.0 —
Ertapenem 0.06 0.06 0.06–0.12 100.0 —
Levofloxacin 0.5 1 0.25–1 100.0 0.0
Erythromycin 0.06 0.06 0.06–8 90.5 9.5
Vancomycin 0.25 0.5 0.25–0.5 100.0 —
-Haemolytic group B streptococci (26)
PPI-0903M 0.016 0.016 0.016 — —
Cefepime 0.12 0.12 0.12 100.0 0.0
Ceftriaxone 0.25 0.25 0.25 100.0 0.0
Penicillin 0.06 0.12 0.03–0.12 100.0 0.0
Meropenem 0.06 0.06 0.03–0.12 100.0 —
Ertapenem 0.06 0.06 0.06–0.12 100.0 —
Levofloxacin 0.5 1 0.25–1 100.0 0.0
Erythromycin 0.06 2 0.06–8 73.1 26.9
Vancomycin 0.5 0.5 0.25–0.5 100.0 —
Other -haemolytic streptococci (20)
PPI-0903M 0.016 0.016 0.016–0.03 — —
Cefepime 0.12 0.5 0.12–0.5 100.0 0.0
Ceftriaxone 0.25 0.25 0.25 100.0 0.0
Penicillin 0.016 0.06 0.016–0.06 100.0 0.0
Meropenem 0.016 0.12 0.008–0.12 100.0 —
Ertapenem 0.06 0.25 0.06–0.5 100.0 —
Levofloxacin 0.5 0.5 0.25–1 100.0 0.0
Erythromycin 0.06 0.06 0.06–2 95.0 5.0
Vancomycin 0.25 0.5 0.25–1 100.0 —
Levofloxacin-resistant -haemolytic
streptococci (10)h
PPI-0903M 0.016 0.016 0.016–0.03 — —
Cefepime 0.12 0.25 0.12–0.25 100.0 0.0
Ceftriaxone 0.25 0.25 0.25 100.0 0.0
Penicillin 0.03 0.06 0.016–0.12 100.0 0.0
Erythromycin 0.06 8 0.06–8 80.0 20.0
Vancomycin 0.5 0.5 0.25–1 100.0 —
Viridans group streptococci
Penicillin susceptible (32)
PPI-0903M 0.016 0.03 0.016–1 — —
Cefepime 0.12 0.25 0.12–0.5 100.0 0.0
Ceftriaxone 0.25 0.25 0.25–0.5 100.0 0.0
Meropenem 0.03 0.06 0.008–0.12 100.0 —
Ertapenem 0.06 0.12 0.06–0.5 100.0 —
Levofloxacin 0.5 1 0.06–2 100.0 0.0
Erythromycin 0.06 1 0.06–8 78.1 18.7
Vancomycin 0.5 1 0.25–1 100.0 —
Penicillin intermediate (53)
PPI-0903M 0.03 0.12 0.016–0.5 — —
Cefepime 0.5 1 0.12–4 90.6 1.9
Ceftriaxone 0.5 2 0.25–4 90.6 1.9
Meropenem 0.12 1 0.06–1 88.0 —
Ertapenem 0.25 2 0.06–2 88.5 —
Levofloxacin 1 4 0.5–4 85.5 10.9
Erythromycin 1 4 0.06–8 35.8 52.8
Vancomycin 0.5 0.5 0.25–1 100.0 —
Continued on following page
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TABLE 1—Continued
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Penicillin resistant (52)
PPI-0903M 0.25 1 0.03–8 — —
Cefepime 4 8 1–16 21.2 53.8
Ceftriaxone 4 16 1–32 9.8 58.8
Meropenem 2 4 0.5–4 16.7 —
Ertapenem 4 8 1–8 11.1 —
Levofloxacin 1 2 0.5–4 94.2 3.8
Erythromycin 2 8 0.06–8 11.5 78.8
Vancomycin 0.5 1 0.25–1 100.0 —
Levofloxacin nonsusceptible (20)
PPI-0903M 0.06 0.25 0.016–1 — —
Cefepime 0.25 4 0.12–8 75.0 15.0
Ceftriaxone 0.25 2 0.25–16 75.0 6.2
Penicillin 0.06 4 0.03–16 55.0 15.0
Erythromycin 0.5 4 0.06–32 45.0 40.0
Vancomycin 0.5 1 0.25–1 100.0 —
Quinupristin-dalfopristin nonsusceptible
streptococci (6)i
PPI-0903M 0.016 — 0.016–8 — —
Cefepime 0.12 — 0.12–16 50.0 50.0
Ceftriaxone 32 — 0.25–32 40.0 60.0
Penicillin 0.12 — 0.016–32 50.0 50.0
Levofloxacin 1 — 1–4 83.3 16.7
Erythromycin 8 — 8 0.0 100.0
Vancomycin 0.5 — 0.25–0.5 100.0 —
Enterococcus faecalis
Vancomycin-susceptible (22)
PPI-0903M 2 16 0.5–32 — —
Ceftriaxone 32 32 32 — —
Ampicillin 2 2 2–8 100.0 0.0
Imipenem 1 4 0.5–8 — —
Levofloxacin 2 4 0.5–4 54.5 45.5
Teicoplanin 2 2 2 100.0 0.0
Linezolid 2 2 0.5–8 86.4 13.6
Vancomycin resistant (22)
PPI-0903M 4 8 1–16 — —
Ceftriaxone 32 32 32 — —
Ampicillin 2 4 2–16 95.5 4.5
Imipenem 2 4 1–8 — —
Levofloxacin 4 4 4 0.0 100.0
Teicoplanin 8 16 2–16 50.0 45.5
Linezolid 1 2 1–8 95.5 4.5
Enterococcus faecium
Vancomycin-susceptible (11)
PPI-0903M 16 32 0.5–32 — —
Ceftriaxone 32 32 16–32 — —
Ampicillin 16 16 2–16 27.3 72.7
Imipenem 8 8 2–8 — —
Levofloxacin 4 4 1–4 18.2 0.0
Teicoplanin 2 2 2 100.0 0.0
Linezolid 1 2 1–2 100.0 0.0
Vancomycin resistant (vanA) (13)
PPI-0903M 32 32 16–32 — —
Ceftriaxone 32 32 32 — —
Ampicillin 16 16 16 0.0 100.0
Imipenem 8 8 8 — —
Levofloxacin 4 4 2–4 7.7 92.3
Linezolid 1 2 1–2 100.0 0.0
Continued on facing page
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The in vitro activities of PPI-0903M in comparison to those
of selected antimicrobial agents against gram-positive patho-
gens are summarized in Table 1. Among all cephalosporins
tested, PPI-0903M shows the greatest activity against gram-
positive organisms, including resistant isolates. PPI-0903M was
very active against S. aureus, including methicillin-resistant
(MRSA) strains. PPI-0903M was 8- to 16-fold more potent
than cefepime and 16- to 32-fold more active than ceftriax-
one against MRSA strains. PPI-0903M was also active against
hetero-vancomycin-intermediate S. aureus (100 strains), with
MIC results ranging from 0.25 to 4 g/ml (MIC at which 50%
of strains were inhibited [MIC50], 1 g/ml; MIC at which 90%
of strains were inhibited [MIC90], 2 g/ml). Furthermore, 91
and 93% of these isolates were resistant to cefepime and ceftri-
axone, respectively. Against 11 quinupristin-dalfopristin-non-
susceptible strains, PPI-0903M MIC results were similar in
activity to that described for MRSA (MIC50 and MIC90, 1
g/ml).
PPI-0903M was slightly more potent against coagulase-neg-
ative staphylococci (CoNS) than against S. aureus. Against
methicillin-resistant CoNS (80 strains), the PPI-0903M MIC50
and MIC90 results were 0.25 and 0.5 g/ml, respectively. PPI-
0903M (MICs, 0.016 to 2 g/ml) was also active against
CoNS (51 strains) having reduced susceptibility to vancomycin
(hVIS; MIC, 4 g/ml). Those hVIS strains were resistant to
other -lactam antibiotics, including imipenem. PPI-0903M
was also active against 15 tested quinupristin-dalfopristin-non-
susceptible strains (MIC90, 1 g/ml). Although all methicillin-
resistant staphylococci should be considered resistant to all
-lactams by the CLSI/NCCLS interpretive criteria (3, 12), the
activities of PPI-0903M against these staphylococci would im-
ply potential clinical utility against MRSA depending upon the
dosing and pharmacokinetics of the molecule. The susceptibil-
ity rates of these isolates to PPI-0903M awaits breakpoint
determination by regulatory and consensus organizations.
As with other -lactams, PPI-0903M in vitro activity against
S. pneumoniae (178 strains; Table 1) varied according to pen-
icillin susceptibility. Penicillin-resistant strains (50 strains;
MIC90, 0.25 g/ml) showed the most elevated PPI-0903M
MICs (0.06 to 0.5 g/ml), but they remained low, and PPI-
0903M potency was generally eightfold greater than that of
either ceftriaxone or cefepime. Resistance to levofloxacin did
not affect PPI-0903M in vitro activity, and multidrug-resistant
strains (resistant to six drugs; see Table 1) were all inhibited by
PPI-0903M at 0.5 g/ml.
PPI-0903M was also very potent against -hemolytic strep-
tococci, with the vast majority of strains inhibited at 0.016
g/ml. The highest PPI-0903M MIC among the -hemolytic
streptococci was only 0.03 g/ml (two group F strains). Levo-
floxacin-resistant -hemolytic streptococci were also very sus-
ceptible to PPI-0903M (MIC90,0.016 g/ml). Viridans group
streptococci susceptibility to PPI-0903M fluctuated according
to the penicillin susceptibility, and resistance to levofloxacin
did not adversely influence the PPI-0903M in vitro activity
against this pathogen. When quinupristin-dalfopristin-nonsus-
ceptible streptococcal strains were tested, PPI-0903M MIC
results varied widely from 0.016 g/ml (two S. bovis strains
and one S. mitis strain) to 8 g/ml (two S. mitis strains).
TABLE 1—Continued
Bacterium group or antimicrobial agent (no. of
isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Linezolid-resistant enterococci (10)j
PPI-0903M 16 32 1–32 — —
Ceftriaxone 32 32 32 — —
Ampicillin 16 16 2–16 40.0 60.0
Imipenem 8 8 0.5–8 — —
Levofloxacin 4 4 1–4 10.0 90.0
Vancomycin 2 16 0.5–16 50.0 40.0
Teicoplanin 2 16 2–16 60.0 40.0
Bacillus spp. (20)k
PPI-0903M 4 8 0.06–32 — —
Cefepime 16 16 2–16 — —
Ceftriaxone 32 32 0.25–32 — —
Penicillin 32 32 0.016–32 — —
Ampicillin 16 16 2–16 — —
Imipenem 0.5 4 0.5–8 — —
Levofloxacin 0.12 0.25 0.06–4 — —
Vancomycin 1 1 0.12–1 — —
a Oxacillin was used in the susceptibility test to categorize staphylococcal isolates as methicillin susceptible or resistant.
b —, no breakpoints have been established by the CLSI/NCCLS (3).
c Oxacillin-resistant S. aureus should be considered resistant to all -lactams according to CLSI/NCCLS (3) recommendations.
d Includes 19 well-characterized vancomycin-intermediate S. aureus (VISA) strains and 81 hetero (h)-VISA strains, using the PAP method and results reported in
an evaluation of AZD2563, an oxazolidinone (16).
e Isolates with vancomycin MIC at 4 g/ml.
f Breakpoints for nonmeningitis isolates were applied (3).
g Resistant to penicillin, erythromycin, clarithromycin, clindamycin, tetracycline, and trimethoprim/sulfamethoxazole.
h Includes one group A, five group B, one group C, two group G, and one ungrouped -haemolytic strain.
i Includes four S. mitis and two S. bovis strains.
j Includes four E. faecalis strains and six E. faecium strains. Resistances confirmed as having G2576U ribosomal target mutations.
k Includes 11 Bacillus cereus strains, one B. circulans strain, and eight Bacillus spp. strains.
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TABLE 2. In vitro activities of PPI-0903M compared to those of selected antimicrobial agents when tested against gram-negative organisms
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Citrobacter freundii (20)
PPI-0903M 0.12 2 0.06–32 — a
Cefepime 0.12 0.25 0.12–1 100.0 0.0
Ceftriaxone 0.25 0.5 0.25–1 100.0 0.0
Ceftazidime 1 2 1–4 100.0 0.0
Piperacillin-tazobactam 2 16 1–64 90.0 10.0
Imipenem 0.5 1 0.5–1 100.0 0.0
Levofloxacin 0.06 0.25 0.03–4 95.0 5.0
Tobramycin 0.5 1 0.25–16 95.0 5.0
Enterobacter cloacaeb
Wild type (23)
PPI-0903M 0.12 32 0.03–32 — —
Cefepime 0.12 2 0.12–4 100.0 0.0
Ceftriaxone 0.25 16 0.25–32 87.0b 8.7
Ceftazidime 1 16 1–16 87.0b 13.0
Piperacillin-tazobactam 2 128 0.5–256 87.0 13.0
Imipenem 0.5 1 0.5–2 100.0 0.0
Levofloxacin 0.03 1 0.03–4 91.3 8.7
Tobramycin 0.5 2 0.25–16 91.3 8.7
ESBL-producing strains (15)
PPI-0903M 32 32 4–32 — —
Cefepime 16 16 8–16 40.0 33.3
Ceftriaxone 32 32 16–32 0.0 86.7
Ceftazidime 16 16 2–16 33.3 53.3
Piperacillin-tazobactam 32 64 2–64 40.0 26.7
Imipenem 0.5 0.5 0.5–8 93.3 0.0
Levofloxacin 4 4 0.03–4 33.3 53.3
Tobramycin 8 16 0.5–16 26.7 46.7
E. coli
Wild type (20)
PPI-0903M 0.06 0.12 0.016–0.25 — —
Cefepime 0.12 0.12 0.12 100.0 0.0
Ceftriaxone 0.25 0.25 0.25 100.0 0.0
Ceftazidime 1 1 1 100.0 0.0
Piperacillin-tazobactam 1 2 0.25–4 100.0 0.0
Imipenem 0.5 0.5 0.5 100.0 0.0
Levofloxacin 0.03 4 0.03–4 80.0 15.0
Tobramycin 0.5 2 0.25–8 90.0 0.0
ESBL-producing strains (15)
PPI-0903M 32 32 0.5–32 — —
Cefepime 16 16 0.12–16 46.7 40.0
Ceftriaxone 32 32 0.25–32 40.0 60.0
Ceftazidime 8 16 1–16 53.3 20.0
Piperacillin-tazobactam 8 32 2–64 86.7 6.7
Imipenem 0.5 0.5 0.5 100.0 0.0
Levofloxacin 4 4 0.03–4 26.7 66.7
Tobramycin 16 16 0.5–16 28.6 64.3
Klebsiella pneumoniae
Wild type (21)
PPI-0903M 0.06 0.5 0.03–4 — —
Cefepime 0.12 0.12 0.12–0.25 100.0 0.0
Ceftriaxone 0.25 0.25 0.25 100.0 0.0
Ceftazidime 1 1 1 100.0 0.0
Piperacillin-tazobactam 2 4 0.5–256 95.2 4.8
Imipenem 0.5 0.5 0.5 100.0 0.0
Levofloxacin 0.06 0.5 0.03–4 90.5 9.5
Tobramycin 0.5 0.5 0.12–2 100.0 0.0
Continued on facing page
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TABLE 2—Continued
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
ESBL-producing strains (15)
PPI-0903M 32 32 32–32 — —
Cefepime 8 16 2–16 60.0 20.0
Ceftriaxone 32 32 16–32 0.0 66.7
Ceftazidime 16 16 1–16 40.0 53.3
Piperacillin-tazobactam 8 256 1–256 58.8 41.2
Imipenem 0.5 0.5 0.5 100.0 0.0
Levofloxacin 0.5 4 0.03–4 60.0 26.7
Tobramycin 16 16 0.5–16 20.0 80.0
Morganella morganii (20)
PPI-0903M 0.06 0.12 0.03–0.5 — —
Cefepime 0.12 0.12 0.12 100.0 0.0
Ceftriaxone 0.25 0.25 0.25–0.5 100.0 0.0
Ceftazidime 1 1 1 100.0 0.0
Piperacillin-tazobactam 0.5 0.5 0.5–2 100.0 0.0
Imipenem 2 4 0.5–4 100.0 0.0
Levofloxacin 0.03 0.12 0.03–1 100.0 0.0
Tobramycin 0.5 1 0.12–2 100.0 0.0
Proteus mirabilis
Wild type (20)
PPI-0903M 0.12 0.12 0.03–4 — —
Cefepime 0.12 0.12 0.12 100.0 0.0
Ceftriaxone 0.25 0.25 0.25–0.5 100.0 0.0
Ceftazidime 1 1 1 100.0 0.0
Piperacillin-tazobactam 0.5 1 0.5–2 100.0 0.0
Imipenem 1 2 0.5–2 100.0 0.0
Levofloxacin 0.06 4 0.03–4 80.0 20.0
Tobramycin 1 2 0.5–8 90.0 0.0
ESBL-producing strains (10)
PPI-0903M 32 32 4–32 — —
Cefepime 16 16 16 0.0 100.0
Ceftriaxone 32 32 1–32 30.0 70.0
Ceftazidime 4 16 1–16 80.0 10.0
Piperacillin-tazobactam 1 2 0.5–32 90.0 0.0
Imipenem 1 2 0.25–2 100.0 0.0
Levofloxacin 4 4 2–4 10.0 80.0
Tobramycin 4 16 0.5–16 60.0 40.0
Providencia spp./P. vulgaris (22)c
PPI-0903M 1 32c 0.03–32 — —
Cefepime 0.12 1 0.12–8 100.0 0.0
Ceftriaxone 0.25 4 0.25–32 90.9 9.1
Ceftazidime 1 1 1–8 100.0 0.0
Piperacillin-tazobactam 0.5 4 0.5–4 100.0 0.0
Imipenem 1 2 0.5–4 100.0 0.0
Levofloxacin 0.06 4 0.03–4 72.7 13.6
Tobramycin 1 4 0.25–16 90.9 4.5
Serratia marcescens (20)
PPI-0903M 0.5 2 0.12–8 — —
Cefepime 0.12 0.25 0.12–0.5 100.0 0.0
Ceftriaxone 0.25 1 0.25–8 100.0 0.0
Ceftazidime 1 1 1 100.0 0.0
Piperacillin-tazobactam 1 4 0.5–16 100.0 0.0
Imipenem 0.5 1 0.5–2 100.0 0.0
Levofloxacin 0.12 0.5 0.06–2 100.0 0.0
Tobramycin 2 4 0.5–16 90.0 5.0
Continued on following page
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TABLE 2—Continued
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Haemophilus influenzae
-lactamase negative (23)
PPI-0903M 0.016 0.016 0.016 — —
Cefepime 0.06 0.12 0.06–0.12 100.0 0.0
Ceftriaxone 0.008 0.008 0.008–0.016 100.0 0.0
Ampicillin 0.5 1 0.5–1 100.0 0.0
Piperacillin-tazobactam 0.12 0.12 0.12 100.0 0.0
Meropenem 0.03 0.12 0.016–0.25 100.0 0.0
Levofloxacin 0.03 0.03 0.03 100.0 0.0
Azithromycin 1 2 0.5–2 100.0 —
-Lactamase positive (24)
PPI-0903M 0.016 0.016 0.016–0.25 — —
Cefepime 0.06 0.12 0.06–1 100.0 0.0
Ceftriaxone 0.008 0.016 0.008–0.06 100.0 0.0
Ampicillin 4 4 2–4 0.0 97.1
Piperacillin-tazobactam 0.12 0.12 0.12 100.0 0.0
Meropenem 0.03 0.06 0.016–0.12 100.0 0.0
Levofloxacin 0.03 0.03 0.03 100.0 0.0
Azithromycin 1 2 0.25–8 95.8 —a
BLNAR (30)d
PPI-0903M 0.016 0.03 0.016–0.03 — —
Cefepime 0.25 0.5 0.06–1 100.0 0.0
Ceftriaxone 0.016 0.6 0.008–2 100.0 0.0
Piperacillin-tazobactam 1 1 1 100.0 0.0
Levofloxacin 0.03 0.03 0.03 100.0 0.0
Azithromycin 1 2 0.12–4 100.0 —
M. catarrhalis (25)e
PPI-0903M 0.06 0.12 0.016–0.12 — —
Cefepime 0.25 1 0.06–2 100.0 0.0
Ceftriaxone 0.06 0.5 0.008–1 100.0 0.0
Ampicillinf 0.5 2 0.5–4 4.0 96.0
Amoxicillin-clavulanic acid 0.06 0.25 0.06–0.5 100.0 0.0
Levofloxacin 0.03 0.03 0.03 100.0 0.0
Azithromycin 0.5 0.5 0.5 100.0 —
Neisseria meningitidis (10)
PPI-0903M 0.016 0.016 0.016 — —
Cefepime 0.12 0.12 0.12 — —
Ceftriaxone 0.25 0.25 0.25 — —
Penicillin 0.016 0.25 0.016–0.25 — —
Ampicillin 1 1 1 — —
Piperacillin-tazobactam 0.5 0.5 0.5 — —
Imipenem 0.5 0.5 0.5 — —
Levofloxacin 0.03 0.03 0.03–0.06 — —
Acinetobacter baumannii (20)
PPI-0903M 16 32 2–32 — —
Cefepime 8 16 2–16 55.0 35.0
Ceftriaxone 16 32 0.5–32 35.0 35.0
Ceftazidime 8 16 2–16 50.0 25.0
Ampicillin-sulbactam 4 32 2–32 70.0 25.0
Piperacillin-tazobactam 32 256 0.12–256 40.0 45.0
Imipenem 0.5 1 0.5–8 95.0 5.0
Levofloxacin 1 4 0.06–4 50.0 50.0
Tobramycin 1 16 0.5–16 65.0 20.0
Alcaligenes spp. (10)g
PPI-0903M 32 32 16–32 — —
Cefepime 16 16 16–16 — —
Ceftriaxone 32 32 16–32 — —
Continued on facing page
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PPI-0903M showed limited activity against both vancomy-
cin-susceptible and -resistant Enterococcus faecium. In addi-
tion, vancomycin-resistant E. faecalis isolates (MIC50, 4 g/ml)
had slightly higher PPI-0903M MICs than vancomycin-suscep-
tible E. faecalis strains (MIC50, 2 g/ml).
PPI-0903M activity was also evaluated against a combined
collection of linezolid-resistant staphylococcal and streptococ-
cal strains, which included seven S. aureus strains (PPI-0903M
MICs, 1 to 4 g/ml), two CoNS strains (PPI-0903M MICs, 0.5
g/ml), and one Streptococcus oralis strain (PPI-0903M MIC,
0.016 g/ml). These PPI-0903M MIC ranges were consistent
with those of linezolid-susceptible staphylococci (data not
shown). Despite the small number of isolates tested, it is con-
cluded that PPI-0903M retained an activity against linezolid-
resistant gram-positive organisms, excluding enterococci.
PPI-0903M was the most active cephalosporin tested against
Bacillus spp. (Table 1), with MIC results ranging from 0.06 to
32 g/ml (MIC50, 4 g/ml, and MIC90, 8 g/ml). Imipenem
(MIC90, 4 g/ml), levofloxacin (MIC90, 0.25 g/ml), and van-
comycin (MIC90, 1 g/ml) also showed reasonable activity
against this pathogen.
The spectrum of activity of PPI-0903M against gram-nega-
tive bacteria is similar to those of the expanded-spectrum ceph-
alosporins. Among the Enterobacteriaceae (221 strains) (Table
2), the vast majority of Citrobacter freundii (MIC90, 2 g/ml),
non-extended-spectrum--lactamase (ESBL)-producing E.
coli (MIC90, 0.12 g/ml) or Klebsiella pneumoniae (MIC90, 0.5
g/ml), Morganella morganii (MIC90, 0.12 g/ml), Proteus
mirabilis (MIC90, 0.12 g/ml), and Serratia marcescens (MIC90,
2 g/ml) were inhibited at 2 g/ml of PPI-0903M. However,
as with other expanded-spectrum cephalosporins, PPI-0903M
MIC results were observed to be elevated for some Enter-
obacter cloacae (MIC90, 32 g/ml), Proteus vulgaris/Providencia
spp. (MIC90, 32 g/ml), and ESBL-producing strains regard-
less of species.
PPI-0903M was highly active against H. influenzae, and its in
vitro activity was not affected by -lactamase production
(MIC90 of 0.016 g/ml) (Table 2). In comparison, -lacta-
mase ampicillin-resistant strains showed PPI-0903M MIC re-
sults that were only slightly elevated (MIC90, 0.03 g/ml).
Moraxella catarrhalis and Neisseria meningitidis strains also
showed low MICs for PPI-0903M (MIC90 of 0.12 g/ml and
0.016 g/ml, respectively) and most of the comparison anti-
microbial agents.
In general, PPI-0903M showed in vitro activity most similar
to that of ceftriaxone and less than that of cefepime or cefta-
zidime against a diverse group of nonfermentative gram-neg-
ative bacilli (60 strains; Table 2). Against anaerobes, PPI-
0903M had excellent activity against some gram-positive
organisms and marginal activity against Clostridium difficile
(MIC50, 2 g/ml, and MIC90, 4 g/ml). Bacteroides fragilis and
TABLE 2—Continued
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Ceftazidime 4 16 2–16 — —
Piperacillin-tazobactam 2 64 0.5–64 — —
Imipenem 2 8 1–8 — —
Levofloxacin 2 4 0.12–4 — —
Tobramycin 16 16 8–16 — —
Pseudomonas aeruginosa (20)
PPI-0903M 16 32 4–32 — —
Cefepime 2 8 1–16 95.0 0.0
Ceftriaxone 32 32 8–32 15.0 60.0
Ceftazidime 2 8 1–8 100.0 0.0
Piperacillin-tazobactam 4 16 2–256 95.0 5.0
Imipenem 1 8 0.5–8 85.0 10.0
Levofloxacin 0.5 4 0.25–4 75.0 25.0
Tobramycin 0.5 16 0.12–16 75.0 25.0
Stenotrophomonas maltophilia (10)
PPI-0903M 32 32 32–32 — —
Cefepime 16 16 4–16 — —
Ceftriaxone 32 32 32–32 — —
Ceftazidime 8 16 1–16 — —
Piperacillin-tazobactam 256 256 8–256 — —
Imipenem 8 8 8 — —
Levofloxacin 1 2 0.25–4 — —
Tobramycin 16 16 16–16 — —
Trimethoprim-sulfamethoxazole 0.5 0.5 0.5 100.0 0.0
a —, no breakpoints have been established by the CLSI/NCCLS (3).
b 13% of isolates produced a stably derepressed AmpC enzyme.
c Two Proteus vulgaris and two Providencia stuartii isolates had PPI-0903M MICs of 32 g/ml.
d BLNAR, -lactamase-negative ampicillin-resistant strains.
e Haemophilus influenzae breakpoints were applied (3).
f Interpreted by -lactamase production or a penicillin MIC at 0.06 g/ml, susceptible (one strain [4.0%] was -lactamase test negative).
g Includes eight A. xylosoxidans strains, one A. faecalis strain, and one Alcaligenes sp. strain.
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Prevotella spp. showed higher PPI-0903M MIC results (MIC90,
32 g/ml) (Table 3).
One of the most striking features of PPI-0903M was its in
vitro activity against gram-positive organisms. Staphylococcus
spp. including MRSA and oxacillin-resistant CoNS appeared
to be particularly susceptible to PPI-0903M (MIC90, 0.25 to 2
g/ml). This finding is important in light of the increasing
prevalence of MRSA in community-acquired infections, in-
cluding community-acquired pneumonia, and in nosocomial
infections (1, 4). In addition, PPI-0903M appears to be active
against vancomycin-nonsusceptible MRSA, a pathogen of con-
cern that has been increasingly documented in recent years (9,
16).
PPI-0903M was also highly active against other key respira-
tory pathogens, such as S. pneumoniae and H. influenzae, which
are common causes of community-acquired pneumonia, otitis
media, and bacterial meningitis. In addition, these pathogens
also represent an important cause of nosocomial pneumonia,
especially when the onset of the disease occurs within 3 to 5
days after hospital admission (13). Mortality and suppurative
complications associated with these infections decrease dra-
matically with the early introduction of appropriate antimicro-
bial therapy (17). The clinical impact of antimicrobial resis-
tance among these pathogens, especially S. pneumoniae, varies
according to the site of infection, reflecting the degree of drug
penetration to that site and the ability of the host immune
response to clear the infection. Thus, antimicrobial resistance
has led to documented treatment failure in patients with men-
ingitis and acute otitis media, but the impact of pneumococcal
resistance on treatment of pneumonia has been more difficult
to determine. High-level -lactam or macrolide resistance has,
however, been associated with increased morbidity and a
longer hospital stay (10, 14). PPI-0903M demonstrated in-
creased in vitro potency compared with currently available
cephalosporins against resistant pneumococci.
Our study showed that PPI-0903M was very active against
many clinically important bacterial pathogens, especially strep-
tococci (-hemolytic, viridans group, and pneumococci), staph-
ylococci (S. aureus and CoNS), H. influenzae, and M. catarrha-
lis. In vitro activity of PPI-0903M against these pathogens was
similar to or more potent than those of other described anti-
MRSA cephalosporins (2, 5, 8, 15). Moreover, PPI-0903M
exhibited activity against several multidrug-resistant gram-pos-
itive pathogens that may cause both community-acquired and
nosocomial infections, including MRSA and penicillin-resis-
tant S. pneumoniae.
While possessing enhanced activity against resistant gram-
positive cocci, PPI-0903M retains in vitro activity against com-
mon gram-negative pathogens. This spectrum of activity dis-
tinguishes it from currently available -lactams and suggests
that PPI-0903 has potential for use in the treatment of bacte-
rial infections in the hospital environment. The prodrug, PPI-
TABLE 3. In vitro activities of PPI-0903M and comparator agents tested against anaerobes
Bacterium group or antimicrobial agent
(no. of isolates tested)
MIC (g/ml) % of isolates by category
50% 90% Range Susceptible Resistant
Bacteroides fragilis (20)
PPI-0903M 32 32 4–32 —a —
Meropenem 0.25 1 0.12–2 100.0 0.0
Metronidazole 1 2 0.5–2 100.0 0.0
Clindamycin 4 16 1–16 35.0 50.0
Clostridium difficile (10)
PPI-0903M 2 4 0.06–8 — —
Meropenem 2 2 1–4 100.0 0.0
Metronidazole 0.5 0.5 0.12–1 100.0 0.0
Clindamycin 4 8 0.5–16 40.0 40.0
Clostridium spp. (16)b
PPI-0903M 0.06 1 0.016–1 — —
Meropenem 0.016 0.5 0.016–1 100.0 0.0
Metronidazole 4 4 0.5–4 100.0 0.0
Clindamycin 0.5 8 0.12–16 68.8 12.5
Other gram-positive anaerobes (14)c
PPI-0903M 0.06 0.12 0.03–0.12 — —
Meropenem 0.12 0.12 0.016–0.12 100.0 0.0
Metronidazole 32 32 1–32 7.1 92.9
Clindamycin 0.25 2 0.12–16 92.9 7.1
Prevotella spp. (16)d
PPI-0903M 8 32 0.03–16 — —
Meropenem 0.12 0.12 0.03–0.25 100.0 0.0
Metronidazole 2 8 1–16 93.8 0.0
Clindamycin 0.12 16 0.12–16 62.5 37.5
a —, no breakpoints have been established by the CLSI/NCCLS (3, 12).
b Includes 12 C. perfringens strains, 3 C. septicum strains, and 1 Clostridium sp. strain.
c Includes two Proprionibacterium acnes strains, nine Proprionibacterium sp. strains, and three Peptostreptococcus sp. strains.
d Includes six Prevotella bivia strains, one P. intermedia strain, one P. melaninogenica strain, two P. oralis strains, and six Prevotella sp. strains.
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0903, is current under the phase I clinical evaluation and has
the potential to be a unique addition to the well-established,
safe cephalosporin class.
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